ACT001 alleviates MASLD through gut microbiota-bile acid-FXR axis in mice.

ABSTRACT:

Background and objective

ACT001 is a novel sesquiterpene lactone derivative with noteworthy antineoplastic and anti-inflammatory properties. This study aimed to investigate the efficacy of ACT001 against metabolic dysfunction associated steatotic liver disease (MASLD) pathogenesis in two established murine models, and to elucidate its regulatory role in the gut microbiota-bile acid-FXR axis.

Materials and methods

A high-fat diet (HFD) and a methionine-choline-deficient (MCD) diet induced two MASLD models in C57BL/6J mice. Histological analysis was performed, biochemical indices were measured, and the expression of tight junctions and farnesoid X receptor (FXR)-related pathways was detected. Gut microbiota was assessed by 16S rDNA sequencing, while bile acids (BAs) in fecal s

SUBMITTER: Niu B 

PROVIDER: S-EPMC12599161 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature